Navigation Links
Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
Date:5/17/2009

ATS 2009, SAN DIEGOCystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease, according to researchers at Parion Sciences in Durham, N.C.

The research will be presented on Sunday, May 17, during the American Thoracic Society's 105th International Conference in San Diego.

"Our results suggest that we have identified a new agent that acts directly on a specific pathway, which is involved in the development of cystic fibrosis," said lead author Andrew Hirsh, Ph.D., senior director of drug discovery and preclinical development for Parion Sciences.

In normal respiration, the moist surface of the airway allows individuals to effectively clear mucous, keeping airways open and viable. But in individuals with cystic fibrosis, the hydration level of the airway is altered and the airway mucous builds up, interfering with normal respiration. One of the mechanisms causing airways to not clear mucous correctly in these patients involves the body's natural homeostasis of sodium which, when absorbed too quickly from the surface of the airway, causes moisture to become absorbed too quickly.

"Cystic fibrosis patients have a genetic ion transport defect, which decreases the hydration level on the airway surface and therefore reduces the body's ability to effectively clear mucous, which is a primary defense mechanism of the respiratory system," Dr. Hirsh said. "Diminished mucous clearance leads to chronic respiratory infection and impaired pulmonary function. Currently there are no therapies available to specifically target this channel in patients with cystic fibrosis."

The aerosol-based therapy uses a specific epithelial sodium channel-blocking agent called GS-9411, which prevents sodium from being absorbed across the airway, allowing the surface to remain moist. The increase in moisture allows individuals to more effectively clear the airway of mucous and infectious agents.

This study was performed during the pre-clinical stage of development to compare GS-9411 to an established epithelial sodium channel blocker, called amiloride. Currently, GS-9411 is in Phase I clinical trials being conducted by Parion's development partner, Gilead Sciences, Inc., in Foster City, CA.

During the study, researchers applied GS-9411 to airway surface cells grown in the laboratory, and assessed the potency and reversibility of the drug on these cells. Results of the study indicated GS-9411 allowed the cells to retain liquid for more than eight hours. Concurrent animal studies revealed that the agent enhanced mucous clearance for more than four hours.

The results offer new hope for cystic fibrosis sufferers, according to Dr. Hirsh. "The potency and the length of time that the drug was effective in cells and in animal studies was an outstanding feature that distinguishes this compound from other agents," he said.

The clinical phase of the drug development cycle will enable researchers to continue to refine the treatment for eventual distribution to cystic fibrosis patients.

"GS-9411 administered by aerosol can effectively increase airway surface liquid and enhance mucous clearance in an animal model," he said. "The results demonstrate that GS-9411 warrants further investigation as a new drug therapy to decrease respiratory infection and improve pulmonary function."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets
2. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
3. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
4. Grocery Manufacturers Association Releases Science Policy Paper on Sodium and Salt
5. Sodium, Potassium Intake Tied to Heart Disease
6. Consumer Reports Identifies Foods With Surprisingly High Levels of Sodium
7. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
8. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
9. Low-sodium advice for asthmatics should be taken with a pinch of salt
10. Low-sodium advice for asthmatics should be taken with a grain of salt
11. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
Breaking Medicine Technology: